If you have knee arthritis, you have probably already been told the standard sequence. Lose some weight. Try physical therapy. Take an anti-inflammatory. Get a cortisone shot. And when those stop working — and they usually do stop working — start thinking about a knee replacement.
Somewhere in that conversation, someone probably mentioned PRP. And you probably went home, searched it, and found a wall of contradictions: clinics calling it the future of orthopedics, and forum posts calling it an expensive placebo. That confusion has been reasonable. For years there was no agreed-upon standard for how PRP should be prepared, dosed, or delivered, so two clinics could both say “we do PRP” and be doing genuinely different procedures.
That changed this year. In April 2026, the American Academy of Physical Medicine and Rehabilitation published a formal guidance statement on platelet-rich plasma for knee osteoarthritis in the journal PM&R — the first widely accepted clinical standard of its kind. Alongside it, two 2026 research syntheses tightened up what the evidence actually shows.
Here is what those documents say, in plain English, and what they mean if you are weighing your options here in Oklahoma City.
What PRP actually is
Platelet-rich plasma starts with your own blood. We draw a sample, spin it in a centrifuge to separate the components, and concentrate the platelet layer. Platelets are best known for clotting, but they also carry growth factors — signaling proteins your body uses to coordinate repair after an injury. That concentrated platelet fraction is then injected into the joint.
The idea is not to add a drug to your knee. It is to deliver a concentrated dose of your own repair signals to a joint where the normal healing response has stalled. Because the material comes from you, the allergic and rejection risks that come with foreign substances are not part of the picture.
Worth saying plainly: PRP is not FDA-approved as a treatment for knee osteoarthritis. It is performed as a physician-directed procedure using your own blood. Any clinic that tells you otherwise is not being straight with you.
What the 2026 AAPM&R guidance statement says
The AAPM&R guidance, published April 16, 2026, was written to close a specific gap. As the Academy put it in announcing the statement, until now there had been no widely accepted standard for delivering PRP in knee osteoarthritis — and that variability in preparation, dosing, and administration had created real clinical uncertainty.
The guidance addresses patient selection, dosing, technique, and informed consent. Two points stand out for patients:
1. It supports considering PRP for mild-to-moderate knee arthritis
The guidance suggests PRP may be considered for patients with mild to moderate knee osteoarthritis who remain symptomatic after conservative treatment — therapy, activity modification, weight management, oral medication. It is positioned as a next step for people that first line has not helped, not as a first move.
2. Waiting may not be the neutral choice patients assume
Expert consensus in the statement indicates that earlier intervention may produce better outcomes than waiting until the arthritis is advanced. This runs against the instinct many patients have, which is to hold off on anything beyond a cortisone shot until things get truly bad. If your cartilage is largely gone, there is less for a biologic signal to work with.
Dr. Prathap Jayaram of Emory University, a co-first author, described the statement as providing an evidence-informed approach for physicians, trainees, and patients alike.
What the 2026 evidence review found
Separately, an umbrella meta-analysis published in Clinics and Practice in 2026 (Ventura-García and colleagues) pooled seven high-quality meta-analyses on PRP for knee osteoarthritis, screened using the AMSTAR 2 methodological tool. Their findings:
- PRP outperformed hyaluronic acid and placebo on both pain and function measures.
- Benefits clustered in the medium term — the 6-to-12-month window after treatment.
- Compared with corticosteroids, the authors described PRP as producing a sustained biological response, with improvements persisting 6 to 12 months, versus the transient effect typical of a steroid injection.
- Results were most pronounced in less severe joint degeneration — Kellgren-Lawrence grades I through III.
- The safety profile was described as remarkably favorable, with adverse events predominantly mild, transient, and local — post-injection soreness or swelling that resolved on its own. No serious adverse events were definitively linked to PRP.
Results vary from patient to patient, and a meta-analysis describes averages across populations, not a prediction for any individual knee.
The finding that explains why PRP results have been so inconsistent
This is the part we think matters most for anyone shopping between clinics.
A 2026 systematic review and meta-analysis by Hooper and colleagues, also in PM&R, found that PRP outcomes in knee osteoarthritis are associated with the total amount of deliverable platelets. A 2025 systematic review in Arthroscopy by Berrigan and colleagues reached a compatible conclusion — that a greater platelet dose may yield better clinical outcomes.
Read that again, because it reframes the whole debate. The question was never simply “does PRP work.” A meaningful part of the question is what was actually in the syringe.
PRP preparation is not standardized across clinics. Different systems, spin protocols, blood volumes, and starting platelet counts produce preparations that can differ several-fold in platelet concentration. A patient who receives a low-concentration preparation and a patient who receives a high-concentration one have both technically “had PRP,” and their experiences may not resemble each other at all. When those patients are pooled together in older studies, the signal washes out.
So when you are comparing providers, the useful questions are not about price alone:
- How is the PRP prepared, and what platelet concentration does that system typically produce?
- Is the injection performed with ultrasound guidance, or by landmark?
- How many sessions are planned, and how far apart?
- What are you asked to avoid before and after — particularly anti-inflammatories, which work against the inflammatory signaling PRP is meant to initiate?
A clinic that can answer those specifically is telling you something. A clinic that cannot is also telling you something.
How we approach this at Venturis Clinic in Oklahoma City
Venturis Clinic is a regenerative, functional, and alternative medicine practice on N May Avenue in Oklahoma City, led by Dr. Alvin Philipose, DC, ICCP. Dr. Philipose has spent more than 25 years in regenerative and functional medicine and has performed thousands of prolotherapy procedures.
Practically, that shapes a few things. Precision of placement matters — an injection that does not reach the intended tissue cannot do much regardless of what is in it. And PRP is not the only regenerative option on the table. Prolotherapy, prolozone, and PRP each have different profiles, and the right choice depends on your imaging, your symptom pattern, your joint, and your goals. We have written before on how prolotherapy and PRP compare and on PRP for joint pain.
Candidates are typically evaluated during a consultation that reviews imaging, prior treatments, activity goals, and general health. Some people are good candidates. Some are not, and we would rather say so.
Who is generally not a good candidate
Being honest about limits is more useful than a list of benefits. PRP is generally not an appropriate option when:
- Arthritis is advanced and joint space is essentially gone — the 2026 evidence points toward better results in earlier-stage disease
- There is an active infection, locally or systemically
- Certain blood, platelet, or clotting disorders are present
- Active cancer is being treated, without oncology coordination
- The expectation is a single injection that permanently resolves the problem — that is not what this is
Some patients who are not candidates for regenerative injections are better served by an orthopedic surgical consultation, and we will say so directly. Some patients simply want to explore what their options are before making a surgical decision, and that is a reasonable thing to want.
Frequently asked questions
Is PRP better than a cortisone shot for knee arthritis?
They work differently. The 2026 umbrella meta-analysis in Clinics and Practice described corticosteroid effects as transient, while PRP produced improvements the authors observed persisting 6 to 12 months. Cortisone can be the right tool for rapid symptom control in certain situations. Which fits you is a question for a clinical evaluation, not an article.
How long does PRP take to work?
PRP is not designed for immediate relief. It initiates a biological process, and published outcome data commonly reports on the 6-to-12-month window. Some patients notice change earlier; some notice little. Results vary.
How many PRP injections are needed?
It depends on the joint, the severity, and the preparation being used. Protocols commonly involve a short series rather than a single injection. Your plan is determined during evaluation.
Is PRP covered by insurance in Oklahoma?
PRP for knee osteoarthritis is generally not covered by insurance and is typically a self-pay procedure. Our team can walk you through specifics before you commit to anything.
Does PRP hurt?
Patients commonly report soreness or a sense of pressure in the joint for a few days afterward. In the 2026 evidence review, adverse events were predominantly mild, transient, and local. That post-injection soreness is generally expected rather than a sign something is wrong.
Can I take ibuprofen after PRP?
Anti-inflammatory medications are typically avoided around PRP treatment, because PRP works partly through an inflammatory signaling cascade that NSAIDs are designed to blunt. Your specific instructions are given at your visit.
Where can I get PRP for knee arthritis in Oklahoma City?
Venturis Clinic is located at 7917 N May Ave, Suite B, Oklahoma City, OK 73120, serving OKC, Edmond, Moore, Norman, Yukon, Mustang, Piedmont, Nichols Hills, Bethany, and Warr Acres. Call (405) 848-7246.
If you want to talk it through
The 2026 guidance did not declare PRP a solved problem. What it did was give patients and physicians a shared reference point where there wasn’t one — and it pointed toward considering these options earlier in the course of knee arthritis rather than as a last resort before surgery.
If you are in the Oklahoma City area and trying to figure out whether regenerative options make sense for your knee, you can request an appointment or book a free 15-minute phone consultation to ask questions before committing to anything. Call (405) 848-7246.
This content is for educational purposes only and is not medical advice, diagnosis, or treatment. Individual results vary and no outcome is guaranteed. Venturis Clinic offers regenerative, functional, and alternative medicine services; some therapies discussed are not FDA-approved for the uses described. Talk with a qualified healthcare provider about your specific situation before beginning any treatment.
Sources
- American Academy of Physical Medicine and Rehabilitation. AAPM&R Guidance Statement on Platelet-Rich Plasma for Knee Osteoarthritis. PM&R, April 16, 2026. doi:10.1002/pmrj.70144
- Ventura-García MÁ, et al. Efficacy and Safety of Platelet-Rich Plasma in Knee Osteoarthritis: Umbrella Meta-Analysis Based on Clinical Evidence, Methodological Quality and Therapeutic Positioning. Clinics and Practice. 2026;16(4):75. doi:10.3390/clinpract16040075
- Hooper N, et al. Platelet-rich plasma outcomes in knee osteoarthritis are associated with the amount of total deliverable platelets: A systematic review and meta-analysis. PM&R. 2026. doi:10.1002/pmrj.13455
- Berrigan WA, et al. A Greater Platelet Dose May Yield Better Clinical Outcomes for Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis: A Systematic Review. Arthroscopy. 2025. doi:10.1016/j.arthro.2024.03.018
